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Condom use to enhance regression of
cervical intraepithelial neoplasia: study
protocol for a randomized controlled trial
Malene Skorstengaard1* , Julie Suhr1 and Elsebeth Lynge2
Abstract
Background: Condom use can reduce the risk of infection by human papillomavirus (HPV). Furthermore, it has
been suggested that condom use can increase the regression rate of cervical lesions. In Denmark, women with
cervical intraepithelial neoplasia grade 2 (CIN2) and a future wish to conceive are not treated immediately but are
followed up by a gynecologist about 6 months later. The aim of this project was to determine if advising women
to have their male partners to use a condom during sexual intercourse in the follow-up period can increase the
regression rate of CIN2.
Methods/design: This is a randomized clinical trial of women with CIN2. The intervention group was advised to
use condoms between the date of diagnosis and the date of their follow-up visit. The control group received
standard care. Cervical samples were tested for HPV. The primary endpoint will be the intention-to-treat analysis
with the relative rate of CIN2 regression between the intervention group and the control group. Regression is
defined as <CIN2 at the follow-up visit. In addition, a per-protocol analysis of the regression rate in women
adhering to condom use compared with the control group will be performed. The secondary endpoint will be the
HPV-clearance rate in the condom group.
Discussion: If condom use for 6 months can enhance the regression of cervical lesions, then more women can be
spared conization. This is an efficient treatment of cervical lesions but is associated with an increased risk of
preterm delivery.
Trial registration: ClinicalTrials.gov, NCT02907333. Registered on 14 September 2016.
Keywords: Cervical lesions, CIN2, condom use, regression rate
Background
In Denmark, women aged 23–49 years are invited to a
cervical screening every 3 years and women aged 50–64
years every 5 years [1]. Liquid-based cytology samples
are collected by their general practitioner [2], and
women with severe abnormalities are referred directly to
a gynecologist. Every year, almost 400,000 cytology sam-
ples are taken, of which 40,000 are abnormal [3], result-
ing in 25,000 biopsies and 6,000 conizations [4]. Control
of cervical cancer via screening, therefore, implies that
many women attend repeated control visits or undergo
conization. In Denmark, conization is performed using
the loop electrosurgical excision procedure [5].
An examination by a gynecologist includes a colpos-
copy, a biopsy, and collecting a cytology sample. If her
histology is normal or she has cervical intraepithelial
neoplasia grade 1 (CIN1), the woman will, according to
national guidelines [6], be followed up by her general
practitioner, who will collect a new cytology sample after
6–12 months. If the woman is diagnosed with CIN2 and
has a wish to conceive in the future, the recommenda-
tion is a follow-up visit to a gynecologist for a biopsy
after 6 months. Women with CIN2 and with no wish to
conceive or postmenopausal women are recommended
to undergo conization. Women with CIN3 are always
recommended to undergo conization [6].
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Persistent infection with high-risk (HR) human papillo-
mavirus (HPV) is a necessary but not sufficient condition
for cervical cancer [7]. HPV is the most common sexually
transmitted infection. Almost 75% of sexually active
women become infected at some point in their life [8].
Most women will clear the infection, but for some women
the infection persists, and for a very small number of
women, the infection progresses to cervical cancer [9].
Male condom use (or, simply, condom use) has been
shown to confer considerable protection against HPV in-
fection, though the protection is less perfect than for
other sexually transmitted diseases [10, 11]. Further-
more, condom use has been hypothesized to improve
the regression rate of cervical lesions [12]. Firstly, con-
dom use may reduce HPV infection and reinfection, and
thereby allow the immune system to repair a cervical le-
sion. Secondly, semen has an immunosuppressive effect,
which is considered an advantage in the reproductive
process, but when cervical lesions have developed, the
absence of semen could benefit the cellular immune re-
sponse [13–15]. Lastly, the latex used for condoms is a
foreign material that could enhance the cellular immune
response and contribute to regression of a cervical
lesion.
Two small studies found an increased regression rate
of cervical lesions when condoms were used in the short
term [16, 17], but this finding was not supported by a
small questionnaire-based study [18]. The studies were
too small to provide conclusive evidence, and condom
use cannot, therefore, be included in the current guide-
lines for the management of CIN.
Objective
The purpose of the present randomized controlled trial
was to provide further evidence for the effect of condom
use on the regression of cervical lesions. The hypothesis
was that the regression rate would increase if condoms
were used consistently for 6 months between the time of
diagnosis and the follow-up visit to a gynecologist.
Methods/design
Patient and public involvement
Focus group interviews were performed prior to the pro-
ject start with women in the relevant age groups. They
advised on the design of the project, the intervention,
and the duration of the intervention. Study participants
were not involved in the recruitment or the conduct of
the study.
Study design
This was a randomized controlled clinical trial embed-
ded in the routine diagnostic and follow-up visits to gy-
necologists for cervical lesions. It was a non-blinded
study with a parallel allocation to an intervention group
and a control group. The randomization ensured that
there were two comparable groups of women, all follow-
ing standard care according to national guidelines [6].
The intervention group were advised to use condoms to
increase the regression rate of cervical lesions. The con-
trol group were not given this advice. Figure 1 is the
SPIRIT diagram for the project.
Target population
Inclusion criteria:
 Premenopausal women with histologically confirmed
CIN2
 Aged 18 to 45 years
 A 6-month follow-up examination with a
gynecologist has been scheduled
Exclusion criteria:
 Women with a latex allergy
 Women who are pregnant
 Women already in a follow-up program for a
cervical lesion
Intervention group
Women in the intervention group are called by the pro-
ject physician and informed about the project. They are
advised always to use condoms during intercourse until
the next follow-up visit with a gynecologist. If they have
not been reached after two calls, a text message is sent.
If they have not been reached after a further two calls
and one text message, they are considered missing.
Those contacted either consent or do not consent to
participate verbally. Participant information and the in-
formed consent form is sent to the home address of
women who consent. Free condoms are sent to the
woman once the signed informed consent form has been
returned to the project physician. As a reminder about
adherence, a text message is sent halfway through the
intervention period. Participating women continue with
their previous contraceptives if any. At the end of the
intervention period, a questionnaire is sent by email.
The questionnaire requests information on use of con-
traceptives, age at first intercourse, lifetime number of
sexual partners, frequency of sexual intercourse, condom
use in the intervention period, number of sexual part-
ners in the intervention period, smoking, number and
time of births and abortions, and HPV vaccination. The
intention was to send the questionnaire to all women in
the intervention group at the time of follow-up. How-
ever, the ethics committee of the Capital Region has
stipulated that the questionnaire is sent only to women
who have consented to condom use.
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For women in the intervention group, their diagnosis
at the follow-up visit with a gynecologist is retrieved
from the pathology register [19]. For participating
women, samples from both baseline and follow-up visits
to a gynecologist are tested for HPV.
Control group
Women in the control group are not contacted by the
project physician and therefore, not given advice on con-
dom use as a way to enhance regression of their cervical
lesions. Otherwise, they are examined and treated in
exactly the same way as women in the intervention
group. The biopsy result from the follow-up visit at the
gynecologist is retrieved from the pathology register.
Setting
The project takes place in three out of the five regions
of Denmark. The project started in September and Oc-
tober 2016 in the Central Denmark Region and Region
Zealand at both public hospitals and with gynecologists
in private practice. The two regions were chosen because
data from the pathology register showed that 700 study
subjects would be expected per year, and the regions had
relatively few stakeholders. To speed up recruitment, the
project was expanded in the fall of 2017 to include some
private practice gynecologists from the Capital Region.
In the Central Denmark Region, all hospitals and all
gynecologists in private practice agreed to participate,
but recruitment was not possible from two gynecologists
in private practice due to logistical challenges. In Region
Zealand, all hospitals and nine gynecologists in private
practice agreed to participate. However, three gynecolo-
gists in private practice did not participate. It was not
possible to recruit patients from one private practice due
to their use of non-standard treatment. The Capital Re-
gion has four gynecology departments and 50 gynecolo-
gists in private practice. We asked 12 gynecologists in
private practice to participate in the project, and five ac-
cepted (Table 1). The project physician has visited all gy-
necologists to provide standardized information.
The gynecologists in hospitals and private practice
send samples to the regional pathology departments for
analysis. In Region Zealand and in the Capital Region,
one pathology department per region is responsible for
the analysis, while the responsibility is shared between
departments in the Central Denmark Region. All path-
ology departments have agreed to send samples for HPV
analysis.
All women included in the study are treated according
to national guidelines. Women referred to a gynecologist
after an abnormal cytology result undergo a colposcopy-
guided biopsy. Samples are taken from sites with visible
cellular changes and also from random sites. It is
Fig. 1 SPIRIT diagram of the project stages. CIN2 Cervical intraepithelial neoplasia grade 2
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recommended that four or five samples are collected
during each biopsy examination. The transformation
zone in the cervical canal should be assessed with a
cytobrush or by endocervical curettage. This procedure
is recommended at the time of diagnosis and at the fol-
low-up visit [6].
Recruitment
Women attending a participating gynecologist are asked
for their phone numbers and to consent to be contacted
by the project physician. Standard information about the
project has been distributed by the project physician to
the gynecologists to ensure standardized information is
given to women. The consent forms are sent from the
gynecologists to the project physician. The consent
forms are matched with new CIN2 diagnoses retrieved
from the pathology register every second week [19]. If
there is a match between a consent form and a CIN2
diagnosis, the gynecologist is contacted for information
about the treatment plan agreed with the woman. If
watchful waiting with a follow-up biopsy in 6 months is
planned, the woman will be included in the project and
randomized (Fig. 2). No side effects, complications, or
risks are expected due to participation in the project.
Randomization
Women meeting the inclusion criteria and for whom we
have received from the gynecologists a phone number
and a signed consent form agreeing to be contacted are
included in the study and randomized with an allocation
of 1:1. The randomization sequence uses a computer-
generated random number list per region, since policies
for follow-ups and treatment vary slightly across the re-
gions. Randomization is undertaken by a third person,
after which the project physician contacts women ran-
domized to the intervention group.
Blinding
The trial is unblinded.
Outcome measures
Primary endpoint
The primary endpoint is the relative rate of CIN2 regres-
sion between women in the intervention group and
women in the control group. Regression is defined as
having a diagnosis < CIN2 in the follow-up biopsy. As
all women have CIN2 at entry, having less than CIN2 at
follow-up entails a decreased risk of conization, and the
woman will be referred back to her general practitioner
for less frequent follow-ups according to national guide-
lines [6]. This outcome is, therefore, highly desirable.
Another primary endpoint is the relative rate of CIN2
regression between women who consented to condom
use and women in the control group. The regression
rate in women who did not consent to condom use will
be used to control for a possible selection bias. Regres-
sion rates will be reported by age.
Secondary endpoint
The secondary endpoint is clearance of HR-HPV for
women who consented to condom use, based on the
baseline sample and the follow-up sample. Clearance is
defined as having a HR-HPV type at the time of CIN2
diagnosis that is not present at the follow-up. Previous
studies have showed that having HPV16 will decrease
the chance of regression of a CIN lesion [20]. Therefore,
the initial HPV status and phenotypes might influence
the regression rate of cervical lesions.
Other outcome measures
Predictors of adherence to condom use, CIN2 regres-
sion, and HR-HPV-clearance based on data on sexual
habits etc., as known from the questionnaire.
Power calculation
Based on the literature [16, 17], we expect the regression
rate in non-condom users to be around 22%, and regres-
sion in condom users to be 2.5 times larger. We expect
the rate of condom use to be 60% in the intervention
group, which gives an expected relative risk of 2.0 for
the intervention group compared to the control group.
With a power of 95% and a 0.05 significance level, we
would need 140 women in each group.
Data analysis plan
The relative regression rate (RRR) for CIN2 in the
intention-to-treat analysis will be calculated as
RRR ¼ number < CIN2 at follow‐up in intervention groupð Þ= all women in intervention groupð Þ
number < CIN2 at follow‐up in control groupð Þ= all women in control groupð Þ :
The relative HPV-clearance rate (RCR) is calculated as
Table 1 Number of gynecologists contributing to the project by region
Region in Denmark Gynecologists in private practice Hospital gynecology departments
Yes No Yes No
Central Denmark Region 7 2 4 0
Capital Region 5 7 Not contacted
Region Zealand 8 4 4 0
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RCR ¼ 1−number HR‐HPV þ at follow‐up in intervention groupð Þ= number HR‐HPV þ at baseline in intervention groupð Þ
1  number HR‐HPV þ at follow‐up in control groupð Þ= number HR‐HPV þ at baseline in control groupð Þ :
These calculations are possible because we have a
closed population, in which all women recruited are
followed up for the entire observation period. Logistic
regression will be used to analyze the questionnaire data
as predictors of outcomes. SAS version 9.4 will be used
for the analysis.
Data sources
From the gynecologists, we will receive the name,
date of birth, and phone number of women who have
consented to be contacted. Every second week, we
will receive a list from the pathology register [19]
with new CIN2 diagnoses. Sample results from the
follow-up visits as well as HPV status at baseline and
follow-up will be retrieved from the pathology regis-
ter. Data on adherence to condom use will be ob-
tained from the questionnaires. All data will be linked
via the women’s unique personal identification num-
ber. The Danish Data Inspective Agency has approved
the handling and storage of data (SUND-2016-21). All
study-related material will be stored safely. Personal
information on the participants is stored in secure
computer systems.
Dissemination
This study was registered at clinicaltrials.gov
(NCT02907333) before recruitment started. This proto-
col article was written according to the Standard
Fig. 2 SPIRIT flowchart of the project design. CIN2 Cervical intraepithelial neoplasia grade 2
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Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guideline [21] (Additional file 1,
Reporting checklist for protocol of a clinical trial).
The project design has been presented at meetings
with the gynecologists. The project protocol has not
been published elsewhere. All results will be analyzed
and published in relevant international peer-reviewed
journals. The results will be presented at international
conferences, to the gynecologists, and to the health
authorities. Furthermore, the results will be dissemi-
nated to the focus group that helped in planning the
study, the study participants, and to the general
public.
Discussion
The use of self-care is increasing as an element of pa-
tient empowerment. Patients want to take part in deci-
sions regarding their treatment and to contribute
actively in optimizing the effect of treatment. For ex-
ample, those with diabetes learn self-management
through blood glucose monitoring [22, 23], those with
chronic obstructive pulmonary disease learn how to use
an inhaler [24], and those with inflammatory bowel dis-
ease learn how to monitor for an upcoming outbreak
and when to start medication [25].
According to the present guidelines from the Da-
nish Society of Gynecology and Obstetrics [6], the de-
cision on whether to follow up or to treat CIN2
immediately is made together with the woman. It
considers whether she wishes to conceive in the fu-
ture. If the decision is made to follow-up only, no ac-
tion is taken before the next visit with the
gynecologist after 6 months and any regression relies
entirely on the ability of the woman’s immune system.
Our project tests a new way for women to intervene
actively in the follow-up period. If the short-term use
of condoms as tested here works as intended, women
will have a choice for self-care and be able to do
something active to enhance the regression rate of
their cervical lesions.
Condom use was tested earlier in two small studies.
Hogewoning et al. [16] ran a randomized controlled
trial and found a statistically significantly increased
regression rate for condom users of 53% (n = 57)
compared with 35% for non-condom users (n = 51).
Munk et al. [17] ran a prospective cohort study, and
found an increased regression rate for condom users
of 55% (n = 20) compared with 22% for non-condom
users (n = 150). We, therefore, expect to find an ap-
proximately 2.5 times increased regression rate in the
condom group compared with the control group [16,
17]. If this new larger study supports the observations
from Hogewoning et al. and Munk et al., we will
suggest temporary condom use to be included in
guidelines to enhance regression of cervical lesions.
Strengths and limitations
A strength of this study is its design as a public health
randomized controlled trial embedded in the routine
treatment and follow-up program for women with cer-
vical lesions. This gives us two groups of women who
are comparable except for the intervention. It is, further-
more, a strength to have three regions included. In
Denmark, health care is paid for by the government and
is free of charge [26], but there are minor regional varia-
tions in clinical procedures, and recruiting participants
from three regions ensures that there is a representative
sample of women.
The number of drop-outs is a limitation in this pro-
ject. We do not receive consent to be contacted from all
women attending a gynecologist, some women in the
intervention group cannot be reached by phone or text
message, and some women do not want to participate.
Participating women may, therefore, be a selected group.
Furthermore, adherence to condom use is inevitably
self-reported. This information is collected from ques-
tionnaires at the end of the project, so there could be
some recall bias. A punch biopsy may alter the HPV in-
fection, and the disappearance of a type-specific HPV in-
fection can be caused either by a biopsy or by an actual
clearance. As the study is embedded in the clinical set-
ting, we are not able to validate histology diagnoses or
perform p16 staining. However, as the routine diagnostic
procedures are used for both the intervention group and
the control group, any possible misclassification will
affect the two groups equally.
Perspectives
If the project shows short-term condom use to enhance
the regression rate of CIN2, this tool can be included in
the guidelines for the management of patients with cer-
vical lesions. Regression reduces the need for conization,
which is associated with a risk of bleeding, infection,
and severe adverse obstetric outcomes [5]. Shortening
the time spent in control and follow-up will also im-
prove the well-being of the women affected [27].
Trial status
The recruitment of women with CIN2 started on 15
September 2016 and the final woman was recruited on
31 January 2019. The trial will end on 30 September
2019, when the last diagnosis from the follow-up will be
made. Protocol version 4 dated 28 June 2016 has been
approved by the ethics committee of the Capital Region.
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